Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome

Br J Dermatol. 2021 May;184(5):978-981. doi: 10.1111/bjd.19720. Epub 2021 Mar 1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Humans
  • Mycosis Fungoides* / drug therapy
  • Sezary Syndrome* / drug therapy
  • Skin Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • mogamulizumab